I dentifying the mechanisms responsible for the progression of Barrett's esophagus (BE) to adenocarcinoma (ADC) is clinically and scientifically relevant. To date, the treatment of BE patients is mainly clinical and the diagnosis largely relies on endoscopic and histopathologic findings. A subset of BE patients are prone to developing low-grade dysplasia (LGD), which, with time, will progress to high-grade dysplasia (HGD) and intramucosal ADC and eventually to invasive ADC. However, the molecular changes responsible for this transition still remain poorly understood.
The cellular apoptosis susceptibility gene (CAS/ CSE1L) has been reported to trigger tumor cell proliferation, apoptosis, tumor invasion, and even metastasis in a variety of human cancers. [1] [2] [3] [4] [5] However, its functional role in BE has not been investigated. The CAS/CSE1L gene encodes a multifunction protein (CAS/CSE1L), which is the human homolog of the yeast cse1 gene. In mice, cse1 is essential for early embryonic growth and development; when mutated, it induces death. 6, 7 CAS/ CSE1L has also been implicated in the nuclear transport of several proliferation-activating proteins, transcription factors, and oncogene and tumor suppressor gene products such as p53. 6, 8 CAS/CSE1L has been recognized as a cellular apoptosis susceptibility gene in colonic, ovarian, urothelial, and breast cancer cells. [1] [2] [3] 5, 9 In these tumor types, CAS/CSE1L facilitates transformation and has an antiapoptotic role. Furthermore, its expression seems associated with an adverse patient outcome in certain tumors, such as colorectal cancer, in which, CAS/CSE1L affects cellular proliferation, apoptosis, cell-cell adhesion, and invasion, thus promoting the progression of colorectal cancer. 1 Interestingly, Jiang et al 3 have reported a close association between K-Ras mutation and CAS/ CSE1L expression, providing a rational strategy for targeting CAS/CSE1L in K-Ras-mutated colorectal cancer. It seems that downregulation of CAS/CSE1L blocks the cell cycle in G2/M and S phases, inhibiting cell proliferation, inducing apoptosis, and suppressing colony growth capacity by colon cancer cells. 1 Therefore, this molecule may also be relevant in BE neoplasia where alterations in cell proliferation and apoptosis seem to have great importance.
The multiple molecular pathways that interplay in the progression of BE to ADC have been defined and include restitution, cell cycle changes, apoptosis, adhesion, DNA instability, and invasion. 10 Following mucosal injury, the mucosa is rapidly healed by restitution. During this phase, in the presence of persistent gastro-esophageal reflux, the metaplastic clones are selected and propagate. Subsequently, cell cycle checkpoint regulation is lost, with genomic instability possibly contributing to slow clonal expansion and increased cell proliferation. 11, 12 At the stage of HGD inhibition of apoptosis occurs. The insurgence of ADC may be preceded by alteration in cell adhesion, 13 and additional cumulative genetic errors may result in the generation of multiple clones of transformed cells, thereby expanding the population of altered cells with an angiogenic or metastatic potential.
Despite these advances in the understanding of tumor progression in BE, the expression and subcellular distribution of CAS/CSE1L in BE and BE-associated neoplasms have not yet been reported in the literature.
In this study, we investigated the cellular expression and distribution patterns of CAS/CSE1L in BE and BE neoplasia in an attempt to detect changes in its expression during the progression of nondysplastic BE to dysplasia, from LGD to HGD and to ADC .
MATERIALS AND METHODS
We obtained esophageal resection specimens for ADC from the Moffitt Cancer Center Pathology repository. All tumors selected had adjacent areas of BE. For each specimen, full sections were selected to include, when possible, BE with no dysplasia (BE, LGD, HGD, and ADC). All patients provided written informed consent to have their samples included in the database. Internal Review Board approval was received for conducting this study.
Immunohistochemical Evaluation of CAS/CSE1L Protein Expression
Overall, 56 ADC tissue samples were stained for CAS/CSE1L expression using a rabbit polyclonal antibody, recognizing the N-terminus of human CAS/CSE1L (clone E10814, dilution: 1:300; retrieval CC2Std; Spring Bioscience, Pleasanton, CA), and the Ventana automated immunostainer Discovery XT (Ventana Medical Systems, Tucson, AZ). CAS/CSE1L overexpression and knockout cell lines were used as controls of specificity. In addition, a section of hepatocellular carcinoma was used as positive control, as recommended by the manufacturer (Fig. 1D) . As a negative control, we used nonimmune mouse sera, omitting the CAS/CSE1L antibody during the primary antibody incubation step. CAS/CSE1L protein expression levels were measured using the Allred semiquantitative scoring system. 14 The data were evaluated by w 2 statistical analysis. P-valuesr0.05 were considered significant.
CAS/CSE1L Gene Expression Analysis Using Public Data Sets
We analyzed CAS/CSE1L gene expression profiles using 3 public data sets from the Gene Expression Omnibus (GEO). 15 Two platforms were considered: the Affymetrix HG-U133A GeneChip and the Illumina Human V2 array. Using GeneAnnot, 16 we found 3 Affymetrix HG-U133A probesets to be of highest quality, which were used for our analysis: 201111_at, 201112_s_at, and 210766_s_at. The 3 data sets consisted of (1) GSE1420 (8 paired normal esophageal epithelium, BE, and esophageal ADC) 17 run on the Affymetrix HG-U133A array; (2) GSE26886 (19 esophageal squamous epithelium from healthy patients, 20 BE, 21 esophageal ADCs, and 9 esophageal squamous cell carcinoma 18 run on the HG-U133A array; and (3) GSE13898 (64 primary esophageal ADCs, 15 BE, and 28 surrounding normal fresh frozen tissues) 19 run on the Illumina Human V2 array. Affymetrix GeneChip data were processed using robust multiarray analysis 20 for normalization. GSE13898 was downloaded directly from GEO. Data were visualized using boxplots, and differences among groups of samples were identified using the Kruskal-Wallis test.
RESULTS

Clinicopathologic Patient Data
The age of the patients ranged between 36 and 82 years (average = 65 y; SD = 9.3 y). Fifty-two patients were male and 4 were female. All patients underwent Ivor-Lewis esophagogastrectomy, including a standard lymph node dissection. The size of the resected tumors ranged between 0.5 and 11.7 cm (mean = 4 cm; SD = 3 cm). There were 56 ADC arising in a background of goblet-cell intestinal metaplasia and all tumors were located in the lower one third of the esophagus. Two representative sections for each case were studied. In 10 cases intestinal metaplasia, in 20 cases LGD, and in 36 cases HGD were present adjacent to the ADC. Three (5.4%) tumors were well differentiated, 28 (50%) moderately differentiated, and 25 (44.6%) poorly differentiated. Four (7.1%) patients had stage I, 18 (32%) stage II, 24 (43%) stage III, and 10 (18%) stage IV disease. Five patients received postoperative chemotherapy. For 8 patients, radiation and chemotherapy were administered after surgical resection; only 2 patients received preoperative chemoradiation. Most of the selected patients did not receive neoadjuvant treatment. Currently, this is not the standard of care, however, the patients in this study were treated several years ago before the new treatment guidelines were adopted.
Immunohistochemical Evaluation of CAS/CSE1L Protein Expression
We detected negative or low CAS/CSE1L expression in BE (immunohistochemistry scores typically were 0 or <2 in BE; Fig. 1A ). CAS/CSE1L reactivity was observed in 60% (12/20) of LGD samples. High CAS/ CSE1L expression levels were seen n HGD and ADC (immunohistochemistry scores >4; Figs. 1B, C). Using the w 2 test, we found significant statistical differences when comparing BE versus LGD, BE versus HGD, BE versus ADC; and LGD versus HGD, and LGD versus ADC (all P-values <0.05) ). There was no statistical significance when comparing HGD with ADC (P = 0.3).
With regard to the cellular distribution of CAS/ CSE1L, our results demonstrated the nuclear localization of CAS/CSE1L in BE. In samples that had progressed to LGD (Figs. 1, 2) , CAS/CSE1L protein expression remained predominantly within the nuclei, but it gradually translocated to the cytoplasm during the progression from LGD to HGD, and ADC (Fig. 2) . Characteristically, the CAS/CSE1L nuclear stain diminished in ADC (Figs. 1C, 2 ).
CAS/CSE1L Gene Expression Analysis Using Public Data Sets
We queried GEO for several data sets consisting of normal esophageal epithelium, BE, and esophageal ADC. In the GSE1420 data set 8 paired normal epithelium, BE, and ADC were profiled. One of 3 probesets (210766_s_at) demonstrated a trend toward increasing CSE1L expression from normal tissue, to BE, to ADC (P = 0.0235, Kruskal-Wallis test) (Fig. 2) .
Interestingly, for GSE26886 data set (19 normal squamous epithelium, 20 BE, and 21 ADCs), CAS/ CSE1L expression levels were lowest in BE, with higher levels shown in ADC and squamous cell carcinoma as well as in esophageal squamous epithelium from healthy patients (P < 6Â 10 À 7 , 0.015). Finally, for the GSE13898 data set (64 ADCs, 15 BE, and 28 surrounding normal tissue), both probes demonstrated a trend of increasing CSE1L expression from LGD to HGD BE, with the highest expression levels shown in ADC (P = 0.0494, 0.0581, Kruskal-Wallis test on 2 probes for CAS/CSE1L).
DISCUSSION
Here we report, for the first time, changes in CAS/ CSE1L protein expression levels during the progression of BE to dysplasia and invasive ADC. Our data indicate that (1) CAS/CSE1L has a functional role early during the progression of BE to invasive ADC and (2) the shuttling of CAS/CSE1L from the nucleus to the cytoplasm during the transition from BE to LGD and to HGD/ADC suggests that the functional transport of this protein is deregulated during the transition from BE to ADC.
BE is diagnosed by a combination of endoscopic and pathologic findings. Histologically BE is characterized by intestinalized columnar metaplasia that extends above the lower esophageal sphincter into the tubular esophagus. BE has about 125-fold increase in risk of developing LGD and HGD and to progress to ADC.
CAS/CSE1L, a protein that regulates cellular proliferation and apoptosis, is synthesized in response to cellular stress and, in non-neoplastic cells, is usually localized to the nucleus. 1, 4, 6, 7, 10, 21, 22 CAS/CSE1L is also involved in the nuclear-cytoplasmic reshuffling of importin-a, 11 in microtubule-associated cellular proliferation, 12 in the migration and invasion of cancer cells, [3] [4] [5] [6] 10, 12, 13, 23 and in the regulation of suppressor genes, such as p53. 21 As far as its role in nuclearcytoplasmic reshuffling of importin-a, the CAS/CSE1L protein is actively transported into and out of the nucleus via distinct nuclear transport pathways, known as RASrelated nuclear protein (Ran). The normal nuclear localization of CAS/CSE1L is maintained by a Ran gradient. 24 Earlier studies have not clarified the impact of CAS/ CSE1L cellular distribution on the carcinogenesis in the upper gastrointestinal tract, including the esophagus.
In this study, we first used public data sets from esophageal cancer gene expression profiling to demonstrate increased CAS/CSE1L expression as a relevant oncogenic modification during the progression of BEassociated neoplasia. Next, we correlated the CAS/ CSE1L protein expression and localization patterns with the different stages of progression of Barrett's neoplasia. Our data show that there is a stepwise upregulation of CAS/CSE1L protein expression during the progression from BE to LGD and from HGD to ADC. It is conceivable that, in ADC, the total amount of CAS/CSE1L protein remains unchanged as compared with HGD, but it is redistributed and dissipated into the cytoplasm. This scenario has been previously depicted in other tumor types where a carcinogenic, proliferative, or antiapoptotic role of CAS/CSE1L was proposed. 4, 5, 21 For example, in colonic ADC, cytoplasmic CAS/CSE1L was reported to correlate with cancer stage, depth of tumor penetration, and lymph node metastasis. 21, 22 The authors suggested that the immunohistochemical analysis of cytoplasmic CAS/CSE1L in colorectal ADC might provide a useful aid to prognostication. 22 Therefore, it is possible that the increased cytoplasmic accumulation of CAS/CSE1L in esophageal ADC may also be utilized as a marker of BE neoplastic progression.
In conclusion, we report for the first time the expression of CAS/CSE1L in BE neoplasia and esophageal ADC. Our findings show a modification in the expression of CAS/CSE1L during the progression of BE to dysplasia and to ADC. Additional studies are warranted to prove the role of CAS/CSE1L in the progression of BE to dysplasia and cancer. The cytoplasmic localization of CAS/CSE1L seems to predict malignant transformation and may represent a prognostic marker in the management of patients with BE.
